NxStage Medical (NXTM) was Upgraded by Northland Capital to ” Outperform”. Earlier the firm had a rating of “Market Perform ” on the company shares. Northland Capital advised their investors in a research report released on Jun 28, 2016.
Many Wall Street Analysts have commented on NxStage Medical. Shares were Resumed by Piper Jaffray on Mar 31, 2016 to “Overweight” and Lowered the Price Target to $ 18.50 from a previous price target of $23 .
On the company’s financial health, NxStage Medical reported $-0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 4, 2016. Analyst had a consensus of $-0.05. The company had revenue of $89.21 million for the quarter, compared to analysts expectations of $88.40 million. The company’s revenue was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.
NxStage Medical opened for trading at $18.9 and hit $19.57 on the upside on Monday, eventually ending the session at $19.46, with a gain of 2.26% or 0.43 points. The heightened volatility saw the trading volume jump to 9,41,715 shares. Company has a market cap of $1,253 M.
In a different news, on May 12, 2016, Joseph E Jr Turk (President) sold 1,500 shares at $17.89 per share price. According to the SEC, on Apr 15, 2016, Jeffrey H Burbank (Chief Executive Officer) sold 10,000 shares at $16.21 per share price. On Apr 15, 2016, Winifred L Swan (SVP and General Counsel) sold 6,260 shares at $16.56 per share price, according to the Form-4 filing with the securities and exchange commission.
NxStage Medical Inc. is a medical device company. The Company is engaged in the development manufacturing and marketing of products for the treatment of kidney failure fluid overload and related blood treatments and procedures. The Companys products include the System One Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product the System One is a small portable easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller portable easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings including patient homes as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One In-Center and Services.